Appointment of Marina Gold as CEO of Mundo Sano.

Alongside with the European & Developing Countries Clinical Trials Partnership (EDCTP) and other international partners, the STOP2030 project is launched with the aim of developing a successful implementation strategy for governments interested in utilizing the new co-formulation of albendazole and ivermectin for the treatment of geohelminthiasis.

The “No Baby with Chagas” campaign is approved as an initiative by the Heads of State and Government of Ibero-America, with the goal of reducing the incidence of congenital Chagas disease transmission. Currently, it includes Argentina, Brazil, Colombia, and Spain as full members, and El Salvador, Guatemala, Honduras and Paraguay as invited countries.

Amid the global health emergency, we have joined various initiatives aimed at finding solutions to address the Covid-19 pandemic. These include participating in the “Covid-19 Clinical Research Coalition”, implementing a pandemic response model in San Antonio de Areco, and collaborating on various activities related to the pandemic.

We launched the “No Baby with Chagas” campaign, committed to raising awareness about the disease to ensure that all babies born with it have access to diagnosis and treatment.

We initiated the STOP project alongside other international partners to evaluate the safety and efficacy of the combination of albendazole and ivermectin in a single pill for the treatment of geohelminthiasis.

Insud Pharma receives approval in the USA for the medication to treat Chagas disease. 25 years later, we fulfil the dream of contributing to public policies through collaboration with international technical organizations such as the World Health Organization and Pan American Health Organization.

We begin working in Africa alongside the Carlos III Health Institute on the diagnosis and treatment of geohelminths.

Uniting to Combat NTDs is introduced, a global alliance driven by the Bill & Melinda Gates Foundation to control and eradicate ten neglected tropical diseases. We are the only Latin American organization integrated into this coalition.

We create the Mundo Sano Foundation in Spain, with the aim of facilitating global work, particularly expanding it into Africa.

A global shortage of treatment for Chagas disease is declared, and Mundo Sano, alongside Elea Laboratories, contributes to Argentina approving the primary medication for treating the disease.

We began our work in Spain focusing on the issue of Chagas disease, which, despite not being endemic in this country, affects migrant Latin American communities. We aim to improve their quality of life through our initiatives.

A period of significant partnerships begins. We establish the organization Uniting to Combat, and join the STH coalition and the Chagas coalition. Mundo Sano decides to participate in the development of medications for neglected diseases.

The concept of our work solidifies as agreements are established with various institutions. Our research expands to include other diseases until our focus is defined towards “neglected diseases”.

Field research work begins. The first few headquarters are established, and efforts commence to develop management models that facilitate decision-making in public policies.

Dr. Gold passes away prematurely in 1996, and the entire family decides that Silvia will take over the Foundation’s presidency.

We begin our contribution to the National Chagas Program. We develop new tools for vector control in collaboration with academic groups and TDR programs. We receive recognition from the Bolívar Program.

Dr. Roberto Gold creates Mundo Sano, a family-owned foundation born with the mission of giving back to society.